AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Primary Objective: To determine the safety of the treatment of relapsed or refractory B cell lymphomas with chimeric antigen receptor T cells targeting cluster of differentiation antigen 19 (CD19) and to find the recommended phase II dose for this cellular therapy Secondary Objectives * To describe the safety profile of the infusion of CAR-T cells targeting CD19. * To describe the toxicities related to infusion of CAR-T cells targeting CD19. * To describe the overall response rate and complete response rate of relapsed B cell malignancies treated with CAR-T cells targeting CD19.